Literature DB >> 2598189

Augmentative effect of Nocardia rubra cell-wall skeleton on the induction of human lymphokine-activated killer (LAK) cells by the production of LAK cell helper factor(s).

T Shirasaka1, I Kawase, M Okada, M Kitahara, T Ikeda, K Komuta, S Hosoe, S Yokota, T Masuno, S Kishimoto.   

Abstract

Nocardia rubra cell wall skeleton (N-CWS) was found to synergistically augment lymphokine-activated killer (LAK) cell generation from human peripheral blood mononuclear cells (PBMC) in the presence of a suboptimal dose of recombinant interleukin-2 (rIL-2). N-CWS increased the number of PBMC expressing IL-2 receptor on their surfaces, and the presence of N-CWS at the early stage of the culture period was essential for the exertion of its augmentative activity on the LAK induction. The predominant phenotype of LAK precursor cells responding to N-CWS and rIL-2 was CD3- CD16+. Culture supernatant from N-CWS-stimulated PBMC was found to act as a substitute for N-CWS in the induction of LAK generation in the presence of rIL-2, suggesting that these cells produced a factor capable of augmenting LAK cell induction (LAK helper factor, LHF). LHF was found to have a molecular mass of 29 kDa by gel filtration, and could also function as a killer helper factor to augment allo-antigen-specific cytotoxic T lymphocyte generation from human peripheral blood T cells as well as murine thymocytes. LHF showed no species specificity, indicating that it is different from IL-4. The enhancing activity of LHF was not neutralized with anti-TNF alpha, anti-IL-1 alpha, or anti-IL-1 beta antibodies. Furthermore, no tumor necrosis factor-alpha (TNF alpha), TNF beta, IL-1 alpha, beta, IL-2, IL-5, IL-6 or interferon activity was detected in semi-purified LHF during enzyme-linked immunosorbant assay and biological assays. The present findings indicate that LHF produced from N-CWS-stimulated PBMC is a molecule distinct from TNF alpha, TNF beta, interferon, IL-1, -2, -4, -5, and -6, and suggest that LHF might be a novel lymphokine involved in LAK generation.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2598189     DOI: 10.1007/bf01665005

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  46 in total

1.  Proposal of standardized methods and reference for assaying recombinant human tumor necrosis factor.

Authors:  S Yamazaki; E Onishi; K Enami; K Natori; M Kohase; H Sakamoto; M Tanouchi; H Hayashi
Journal:  Jpn J Med Sci Biol       Date:  1986-06

2.  Purification and characterization of recombinant human interleukin-2 produced in Escherichia coli.

Authors:  K Kato; T Yamada; K Kawahara; H Onda; T Asano; H Sugino; A Kakinuma
Journal:  Biochem Biophys Res Commun       Date:  1985-07-31       Impact factor: 3.575

3.  Association of macrophage activation with antitumor effect on rat syngeneic fibrosarcoma by Nocardia rubra cell wall skeleton.

Authors:  T Ogura; N Namba; F Hirao; Y Yamamura; I Azuma
Journal:  Cancer Res       Date:  1979-11       Impact factor: 12.701

4.  Mechanism(s) of in vitro macrophage activation with Nocardia rubra cell wall skeleton: the effects on macrophage activating factor production by lymphocytes.

Authors:  T Masuno; S Hayashi; M Ito; T Ikeda; T Ogura; S Kishimoto; Y Yamamura
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

5.  Randomized controlled study of chemoimmunotherapy of acute myelogenous leukemia (AML) in adults with Nocardia rubra cell-wall skeleton and irradiated allogeneic AML cells.

Authors:  R Ohno; H Nakamura; Y Kodera; K Ezaki; S Yokomaku; S Oguma; Y Kubota; H Shibata; N Ogawa; T Masaoka
Journal:  Cancer       Date:  1986-04-15       Impact factor: 6.860

6.  Transforming growth factor-beta 1 (TGF-beta 1) and recombinant human tumor necrosis factor-alpha reciprocally regulate the generation of lymphokine-activated killer cell activity. Comparison between natural porcine platelet-derived TGF-beta 1 and TGF-beta 2, and recombinant human TGF-beta 1.

Authors:  T Espevik; I S Figari; G E Ranges; M A Palladino
Journal:  J Immunol       Date:  1988-04-01       Impact factor: 5.422

7.  B cell stimulatory factor-2 is involved in the differentiation of cytotoxic T lymphocytes.

Authors:  Y Takai; G G Wong; S C Clark; S J Burakoff; S H Herrmann
Journal:  J Immunol       Date:  1988-01-15       Impact factor: 5.422

8.  Distinction of partially purified human natural killer cytotoxic factor from recombinant human tumor necrosis factor and recombinant human lymphotoxin.

Authors:  T Bialas; J Kolitz; E Levi; A Polivka; S Oez; G Miller; K Welte
Journal:  Cancer Res       Date:  1988-02-15       Impact factor: 12.701

9.  The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo.

Authors:  J J Mulé; S Shu; S A Rosenberg
Journal:  J Immunol       Date:  1985-07       Impact factor: 5.422

10.  Establishment and characterization of human T hybrid cells secreting immunoregulatory molecules.

Authors:  M Okada; N Yoshimura; T Kaieda; Y Yamamura; T Kishimoto
Journal:  Proc Natl Acad Sci U S A       Date:  1981-12       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.